In This Article:
What Happened?
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 17.5% in the afternoon session after the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA guidance that fell short of Wall Street's estimates.
On the other hand, Omnicell blew past analysts' EPS and revenue estimates. Still, this was a weaker quarter.
The shares closed the day at $25.62, down 16% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Omnicell? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Omnicell’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Omnicell and indicate this news significantly impacted the market’s perception of the business.
Omnicell is down 42.6% since the beginning of the year, and at $25.46 per share, it is trading 52% below its 52-week high of $53.05 from October 2024. Investors who bought $1,000 worth of Omnicell’s shares 5 years ago would now be looking at an investment worth $350.35.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.